Pharmaceuticals
  • Eli Lilly and Company is a global pharmaceutical company whose scale, metabolic-medicine franchise, and drug-development pipeline make it a key organization to track in biopharma.
  • Eli Lilly and Company is a for-profit pharmaceutical company focused on discovering, developing, manufacturing, and commercializing medicines. The company was founded in 1876 and is headquartered in Indianapolis, Indiana; its operations and markets are global. Its recent growth has been driven prominently by Mounjaro and Zepbound, which together helped produce third-quarter 2026 revenue of $24.4 billion. [wozll6]

Identity and Form

  • Type: This organization is a for-profit company.
  • Legal form and jurisdiction: Public company, incorporated in the United States and traded on the New York Stock Exchange under ticker LLY . [denp3x]
  • Headquarters and presence: Indianapolis, Indiana; global commercial, research, and manufacturing operations. [wozll6]
  • Size: No reliable current headcount figure was available in the returned search results.
  • Where it lives online: Homepage · Investor relations · Newsroom

Mission and Identity

ℹ️
“We make medicines that help people live longer, healthier, more active lives.” [denp3x]
Lilly presents itself as a medicine company organized around discovering and delivering treatments for serious health conditions. Its public identity emphasizes scientific innovation, patient health, and expanding access to medicines rather than operating as a diversified healthcare conglomerate. [denp3x]
  • Stated values: The returned results did not provide a reliable source listing Lilly’s current formal values or operating principles.

What They Do

Lilly conducts pharmaceutical research, runs clinical-development programs, manufactures medicines, and sells approved therapies through healthcare systems and patients worldwide. Its portfolio spans metabolic disease, diabetes, obesity, oncology, immunology, neuroscience, and other therapeutic areas. [wozll6] [denp3x]
  • Mounjaro: tirzepatide for type 2 diabetes; a major revenue driver. [wozll6]
  • Zepbound: tirzepatide for chronic weight management; a major revenue driver. [wozll6]
  • Verzenio: abemaciclib for breast cancer. [denp3x]
  • Retevmo: selpercatinib for certain cancers. [denp3x]
  • Taltz: ixekizumab for inflammatory and immune-mediated conditions. [7p90km]
  • Jaypirca: pirtobrutinib for certain blood cancers, including expanded use in previously untreated CLL/SLL. [wozll6]
  • Clinical pipeline: investigational programs include retatrutide, orforglipron, olomorasib, and sofetabart mipitecan. [wozll6] [denp3x] [t5m7ja] [60mbnv] [ikthd6]

Leadership and People

  • David A. Ricks — chair and chief executive officer; leads Lilly’s global pharmaceutical business. [denp3x]
  • Patrik Jonsson — executive vice president and president, Lilly International; announced retirement at the end of 2026 after a 36-year Lilly career. [g3x3xn]
  • Ilya Yuffa — named executive vice president and president, Lilly Global Markets, effective January 1, 2027. [g3x3xn]
  • Laura Steele — named president, Lilly USA, effective January 1, 2027. [g3x3xn]

History and Origin Story

Eli Lilly founded the company in Indianapolis in 1876 with the aim of producing higher-quality medicines through pharmaceutical science and manufacturing discipline. The organization has since evolved into a global research-based pharmaceutical company whose recent strategic center of gravity is metabolic medicine alongside oncology, immunology, and other specialty areas. [denp3x]
  • 1876 — Colonel Eli Lilly founded the company in Indianapolis. [denp3x]
  • 2020 onward — Lilly announced a program of major U.S. manufacturing expansion, ultimately describing more than $50 billion in planned investment. [60eora]
  • 2026 — Lilly reported that Mounjaro and Zepbound were central drivers of its rapid revenue growth. [wozll6]
  • October 2026 — Lilly broke ground on a planned $5 billion integrated manufacturing facility in Virginia. [60eora]
  • 2026 — Lilly expanded its oncology pipeline through clinical development of investigational ADC and KRAS G12C programs. [denp3x] [60mbnv] [ikthd6]

Financials and Funding

  • Market capitalization: No reliable current market-capitalization figure was available in the returned search results.
  • Latest reported revenue: $24.4 billion in third-quarter 2026, up 39% year over year. [wozll6]
  • Latest reported net income: No reliable net-income figure was included in the returned search results.
  • Dividend: The board declared a fourth-quarter 2026 dividend of $1.73 per share. [q22din]
  • Ticker and exchange: LLY, New York Stock Exchange. [denp3x]

Milestones and Signature Output

  • Mounjaro — 2026 — tirzepatide became one of Lilly’s principal commercial growth drivers in type 2 diabetes. [wozll6]
  • Zepbound — 2026 — tirzepatide-based obesity treatment became another major contributor to Lilly’s revenue expansion. [wozll6]
  • [Jaypirca expanded indication] — 2026 — the FDA expanded use for certain patients with previously untreated CLL/SLL. [wozll6]
  • [Olumiant pediatric indication] — 2026 — the FDA approved use in patients aged 12 and older with severe alopecia areata. [wozll6]
  • [Richmond manufacturing facility] — 2026 — Lilly broke ground on a $5 billion site designed to produce both active pharmaceutical ingredients and finished medicines. [60eora]
  • [Retatrutide Phase 3 data] — 2026 — Lilly reported topline results from a head-to-head trial against injectable semaglutide in adults with type 2 diabetes. [t5m7ja]
  • [Olomorasib oncology program] — 2026 — Lilly presented new data for an investigational KRAS G12C inhibitor in first-line advanced non-small-cell lung cancer. [60mbnv]
  • [Sofetabart mipitecan oncology program] — 2026 — Lilly presented early data for an investigational FRα-targeting antibody-drug conjugate in platinum-sensitive ovarian cancer. [ikthd6]

Ecosystem and Relationships

  • New York Stock Exchange: Lilly’s publicly traded shares use the ticker LLY. [denp3x]
  • U.S. Food and Drug Administration: The FDA is the principal U.S. regulator associated with Lilly’s drug approvals and indication expansions. [wozll6]
  • European Society for Medical Oncology: Lilly presented oncology pipeline data at the 2026 ESMO Congress. [denp3x] [60mbnv] [ikthd6]
  • Manufacturing ecosystem: Lilly’s Virginia investment is part of a broader U.S. manufacturing expansion involving active pharmaceutical ingredients and finished medicines. [60eora]
  • Competitive metabolic-medicine landscape: Lilly’s retatrutide trial compared its investigational therapy with injectable Ozempic 2 mg, identifying Novo Nordisk as a major competitor in this therapeutic category. [t5m7ja]

Recent Developments

As of 2026-11-04,
  • October 30, 2026 — Lilly reported third-quarter revenue of $24.4 billion, up 39% year over year, and raised its full-year outlook. [wozll6]
  • October 30, 2026 — Lilly reported positive topline Phase 3 results for retatrutide in a head-to-head type 2 diabetes study against injectable Ozempic 2 mg. [t5m7ja]
  • October 30, 2026 — Lilly announced leadership succession plans involving Ilya Yuffa, Laura Steele, and Elias Khalil, following Patrik Jonsson’s planned retirement. [g3x3xn]
  • November 3, 2026 — Lilly’s Richmond, Virginia, manufacturing project was updated as a $5 billion facility within a broader U.S. production investment exceeding $50 billion. [60eora]
  • October 31, 2026 — Lilly reported new oncology data for olomorasib and sofetabart mipitecan at the 2026 ESMO Congress. [60mbnv] [ikthd6]

Impact

  • Impact on society
    • Lilly’s Mounjaro and Zepbound franchises have reached sufficient commercial scale to drive $24.4 billion in quarterly company revenue, indicating substantial uptake of Lilly’s metabolic medicines. [wozll6]
    • Lilly’s products and pipeline target high-burden conditions including diabetes, obesity, cancer, autoimmune disease, and alopecia areata. [wozll6] [denp3x]
  • Impact on innovation
    • Lilly is accelerating research around incretin-based metabolic medicines, including next-generation investigational candidates such as retatrutide and oral orforglipron. [wozll6] [t5m7ja]
    • Its oncology pipeline includes antibody-drug conjugates and KRAS G12C inhibition, two approaches represented in the company’s 2026 clinical disclosures. [denp3x] [60mbnv] [ikthd6]
  • Impact on its industry or domain
    • Lilly’s metabolic portfolio has become a major competitive force in diabetes and obesity therapeutics, with Mounjaro and Zepbound identified as the primary drivers of 2026 revenue growth. [wozll6]
    • Its planned $5 billion Virginia site illustrates the pharmaceutical industry’s shift toward large-scale, vertically integrated domestic manufacturing for complex medicines. [60eora]
  • Historical significance
    • Founded in 1876, Lilly is one of the long-established U.S. research-based pharmaceutical companies and remains a major participant in the modern pharmaceutical industry. [denp3x]
  • Criticisms and controversies
    • No reliable independent reporting on a substantive controversy was included in the returned search results; this section is therefore limited rather than padded.

Adjacent Entries

Sources

[wozll6] 2026, Oct 29. investor.lilly.com . Lilly reports third-quarter 2026 financial results, raises full ... . Updated: 2026, Oct 30. Generated: 2026, Nov 03. Perplexity API response.

[denp3x] 2026, Oct 18. investor.lilly.com . Lilly to showcase advances across its oncology pipeline at ... . Updated: 2026, Oct 27. Generated: 2026, Nov 03. Perplexity API response.

[60eora] 2026, Oct 22. investor.lilly.com . Lilly breaks ground in Richmond to expand American ... . Updated: 2026, Nov 03. Generated: 2026, Nov 03. Perplexity API response.

[t5m7ja] 2026, Oct 28. investor.lilly.com . Lilly's retatrutide delivered greater A1C reduction and more ... . Updated: 2026, Oct 30. Generated: 2026, Nov 03. Perplexity API response.

[g3x3xn] 2026, Oct 27. investor.lilly.com . Patrik Jonsson to retire after 36 years; Ilya Yuffa named ... . Updated: 2026, Oct 30. Generated: 2026, Nov 03. Perplexity API response.

[q22din] 2026, Oct 26. investor.lilly.com . Lilly declares fourth-quarter 2026 dividend | Eli Lilly and ... . Updated: 2026, Oct 29. Generated: 2026, Nov 03. Perplexity API response.

[60mbnv] 2026, Oct 25. investor.lilly.com . New data on Lilly's investigational treatment olomorasib at ... . Updated: 2026, Oct 31. Generated: 2026, Nov 03. Perplexity API response.

[ikthd6] 2026, Oct 24. investor.lilly.com . Lilly presents first clinical data in platinum-sensitive ovarian ... . Updated: 2026, Oct 31. Generated: 2026, Nov 03. Perplexity API response. [9]: 2026, Oct 15. investor.lilly.com . Lilly confirms date and conference call for third-quarter ... . Updated: 2026, Oct 16. Generated: 2026, Nov 03. Perplexity API response.

[7p90km] 2026, Oct 09. investor.lilly.com . New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound ... . Updated: 2026, Oct 31. Generated: 2026, Nov 03. Perplexity API response.